{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "LEGN",
  "name": "Legend Biotech Corporation",
  "url": "https://orbyd.app/dossiers/LEGN/",
  "json_url": "https://orbyd.app/dossiers/LEGN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst until the ~8/12 Q2 CARVYKTI read; sell-the-news gap-fade is the live near-term risk.",
  "invalidation_trigger": "A weekly close below $25.50 fills the pre-data gap and negates the in-vivo CAR-T re-rate; the $29.35 June offering price is the nearer warning shelf. Secondary: a soft Q2 CARVYKTI sales read at the ~2026-08-12 print, or an in-vivo peer printing competing human durability data that flips the theme to saturated.",
  "catalyst_date": "2026-08-12",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-15",
  "invalidation_fired": true,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Narrative has cooled from ACCELERATING (June re-rate) to MATURING/DORMANT digestion. Spike faded into a discounted raise; Street PTs drifting DOWN (RBC $64→$63 on 7/7, JPM reinstated Neutral $35 on 7/13).",
    "6/17 $226M raise: 7.7M ADS @ $29.35 + 1.155M over-allotment, closed ~6/23. Offering price = the near-term supply anchor. Management raised into the pop rather than holding for higher — read that as a fair-value tell near $29–33.",
    "EHA full data (6/13) already RESOLVED and clean: 100% ORR / 83.3% CR at higher dose, 12 dosed pts, no DLTs/SAEs/ICANS/deaths, CRS Gr 1-2. This is continuation, not a fresh binary. Sell-the-news gap-fade is the primary risk.",
    "CARVYKTI is ~50/50 economics with J&J — LEGN banks roughly half of net trade sales; model the partner split. J&J Q2 (mid-July) CARVYKTI read is now elapsed/priced; LEGN's own Q2 (~8/12 est) is the next hard fundamental check.",
    "Tiny-n & fragile: 100% ORR at the higher dose is a small cohort with short follow-up ('ongoing at cutoff'). In-vivo CAR-T durability/safety at scale unproven; LB2102 solid-tumor (DLL3) ORR was only ~20%.",
    "In-vivo peer set (EsoBiotec/AstraZeneca, Capstan/AbbVie, Interius, Umoja) is mostly PRECLINICAL — a competing HUMAN durability print is the biggest threat to the theme premium, bigger than any single CARVYKTI quarter.",
    "52wk range $16.25–$45.30. Structure lines: pre-data gap base ~$25–26 (6/1 close), offering shelf $29.35, post-data high $36.28 (6/2). Reclaim of $36.28 on volume reopens the momentum leg; loss of $29.35 puts the gap-fill in play.",
    "LEGN Q2 date (~2026-08-12) is ESTIMATED from prior-year mid-August pattern — verify exact date before sizing around it."
  ],
  "body_markdown": "## Current Thesis\nThe in-vivo CAR-T re-rate has run its first leg and settled into digestion. The late-breaking LB2501 dataset at EHA Stockholm (2026-06-13) confirmed the topline that gapped the stock roughly +42% on 2026-06-02: a 100% objective response rate and 83.3% complete-response rate at the higher dose across 12 dosed patients, durable CAR-T persistence, rapid vector clearance, no lymphodepletion, and no DLTs/SAEs/ICANS/deaths, with CRS held to Grade 1–2 and managed without glucocorticoids. The durability question that was the going-in swing printed clean. The tape refused to reward it: $36.28 (6/2) bled to $32.62 (6/5), and on 2026-06-17 management priced a $226M raise — 7,700,000 ADSs at $29.35, a discount to the then-$33.52 quote plus a 1,155,000-ADS over-allotment — with the stock settling right at that offering (~$29.34, 6/22). Confirmed-positive data, a lower price, a fresh dilution anchor, and a Street that is cooling rather than chasing — the setup reads as a maturing narrative absorbing a spike, with no dated binary to force the next leg.\n\n## Bull Case\n- **Durability confirmed at EHA (2026-06-13):** LB2501 (in-vivo CD19/CD20 dual-targeting CAR-T for R/R B-NHL) showed dose-dependent in-vivo expansion, 100% ORR / 83.3% CR at the higher dose across 12 dosed patients, durable persistence, and no non-specific transduction — the exact safety/durability profile bears flagged as the risk held up.\n- **Balance sheet de-risked (2026-06-17):** the $226M raise (7.7M ADS @ $29.35, closed ~6/23) funds in-vivo platform expansion and clears a financing overhang that had capped the risk appetite for the story.\n- **Bull-camp targets still sit well above tape:** HC Wainwright Buy $65, RBC Outperform $63 (from $64), UBS Buy $49 — against a ~$29–35 quote the price trades at roughly half the high bar.\n- **First human proof-point in the in-vivo race (2026-06-02):** AstraZeneca/EsoBiotec, AbbVie/Capstan, Interius and Umoja remain largely preclinical, while Legend holds a 100%-ORR human cohort.\n- **Funded commercial engine:** CARVYKTI (cilta-cel, BCMA, J&J-partnered) remains the fastest-ramping commercial cell therapy and bankrolls the in-vivo pipeline; J&J's mid-July Q2 print is the fresh checkpoint on that ramp.\n\n## Bear Case\n- **Sell-the-news plus dilution:** $36.28 (6/2) → $32.62 (6/5) → discounted raise at $29.35 (6/17) → $29.34 (6/22). The stock fell on confirmed-positive data and then took a discounted equity print at the lows of the move.\n- **Raising into the pop signals management's own read:** issuing ~4% new ADSs plus over-allotment at $29.35 rather than holding for higher implies the sellers judged ~$29–33 a fair clearing price.\n- **Still tiny-n:** 100% ORR is 12 dosed patients at the higher dose with short follow-up (\"ongoing at cutoff\"); in-vivo CAR-T durability and safety at scale are unproven, and the LB2102 solid-tumor (DLL3) cohort managed only ~20% ORR.\n- **Street is split and drifting lower:** JP Morgan reinstated Neutral $35 (7/13), Morgan Stanley lowered to $48 (6/3, still Overweight), TD Cowen stays Hold near $29 — the bull/bear PT spread runs $29–$65 and even bulls are trimming.\n- **CARVYKTI economics are shared and contested:** roughly 50/50 with J&J, so Legend banks about half of net trade sales, while BMS (Abecma) and Arcellx/Gilead (anito-cel) press the BCMA myeloma base and the FDA class boxed warning on secondary T-cell malignancy sits over the field.\n\n## Setup & Price Structure\nNo live price/MA/RSI context was supplied this cycle, so structure is provisional — treat any fresh entry as a probe until clean levels print. The reference frame from the June move: the gap/breakout base sits ~$25–26 (6/1 close, pre-data), the June offering anchors supply at $29.35, and the post-data high was $36.28 (6/2) before the fade to $32.62 (6/5). The 52-week range is $16.25–$45.30. The spike overbought condition has bled off toward the offering price, and JP Morgan's $35 target (7/13) roughly brackets the top of the recent digestion band, implying the low-conviction case sees limited near-term upside from here. A move that reclaims and holds above $36.28 on volume would reopen the momentum leg; loss of the $29.35 offering shelf puts the pre-data gap in play.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-08-12 (est.):** Legend Biotech Q2 2026 earnings — the hard fundamental check is the Q2 CARVYKTI net-trade-sales line (partner-split), plus any in-vivo pipeline/enrollment update. This is the only dated near-term binary and sits near the edge of the 30-day window (date estimated from the mid-August prior-year pattern; verify before sizing).\n- **Elapsed context (already priced):** J&J Q2 print (mid-July) delivered the CARVYKTI sales read that had been the near-term fundamental swing; EHA full data is done (6/13). No fresh medical-congress catalyst falls inside the window — the next major hematology venue lands in the fall, outside 30 days.\n\n## What Would Change Our Mind\nA weekly close below $25.50 fills the pre-data gap and negates the in-vivo CAR-T re-rate outright; the $29.35 June offering price is the nearer warning shelf, and losing it cleanly signals the dilution supply has taken control. To the upside, a decisive volume reclaim above the $36.28 post-data high would flip the read from digestion back to an accelerating leg and justify sizing beyond a probe. On fundamentals, a soft or decelerating CARVYKTI sales read at the ~2026-08-12 Q2 print, or an in-vivo peer publishing competing human durability data, would flip the theme toward saturated and remove the \"first-and-only human proof\" premium the bull case rests on.\n\n## Correlation Notes\nLEGN trades as a high-beta cell-therapy name: directionally tied to the CAR-T/in-vivo cohort (Arcellx, CRSP, NTLA, BEAM) and to XBI/IBB biotech risk appetite, so a rate-driven small-cap-biotech drawdown hits it regardless of company news. Idiosyncratic exposure runs through CARVYKTI's shared economics with J&J — the stock reacts to J&J's oncology commentary and to BMS/Gilead-Arcellx BCMA competitive prints. The in-vivo narrative is the swing factor: correlation to preclinical peers (EsoBiotec/AstraZeneca, Capstan/AbbVie, Interius, Umoja) is thematic, and a competing human dataset there is a bigger risk to the multiple than any single CARVYKTI quarter.",
  "first_seen": "2026-04-22",
  "last_analyzed": "2026-07-18T08:03:40+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}